

Alberta Drug Benefit List (ADBL) Interim Update now available online

The August 1, 2025 Updates to the *Alberta Drug Benefit List (ADBL)* are now available online at ab.bluecross.ca/dbl/publications.php

Please refer to the **August 1, 2025** updates for complete listings of products available by special authorization, restricted benefit/special authorization, added products, new established interchangeable groupings, least cost alternative price changes, products with a price change, and discontinued listings.

Please note that the online *interactive Drug Benefit List (iDBL)* at ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application and contains the most up-to-date information.

Temporary benefits added to the ADBL

Due to the unavailability of Spironolactone 25 mg Tablet (DIN 02518821), Mint-Spironolactone 25 mg Tablet (DIN 02488140) and Teva-Spironolactone 25 mg Tablet (DIN 00613215), **Aldactone 25 mg Tablet (DIN 00028606)** manufactured by Pfizer Canada ULC will be considered a temporary benefit for the ADBL. This grouping was added to the Critical Supply Product List on **July 15, 2025**.

As of **July 15, 2025**, all claims for **Aldactone 25 mg Tablet (DIN 00028606)** will be adjudicated to the price published in the most recent *Alberta Blue Cross® Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/provider/type/pharmacy/price-files.php

Due to the unavailability of Jamp Spironolactone 100 mg Tablet (DIN 02518848), Mint-Spironolactone 100 mg Tablet (DIN 02488159), and Teva-Spironolactone 100 mg Tablet (DIN 00613223), **Aldactone 100 mg Tablet (DIN 000285455)** manufactured by Pfizer Canada ULC will be considered a temporary benefit for the ADBL. This grouping was added to the Critical Supply Product List on **July 16, 2025**.

As of **July 16, 2025**, all claims for **Aldactone 100 mg Tablet (DIN 000285455)** will be adjudicated to the price published in the most recent ABCDPL until further notice. The ABCDPL is available online at ab.bluecross.ca/provider/type/pharmacy/home.php

Product supply shortages resolved for ADBL

Alberta Blue Cross® has confirmed that the shortage for Taro-Tofacitinib 10 mg Tablet (DIN 02511312) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied. As a result, the LCA Price Policy will be reapplied to the following grouping effective **August 15, 2025**. The following grouping was removed from the Critical Supply Product List on **July 16, 2025**:

TOFACITINIB CITRATE

10 MG TABLET

00002530015	AURO-TOFACITINIB	AUR	\$ 21.1718
00002511312	TARO-TOFACITINIB	TAR	\$ 21.1718
00002480786	XELJANZ	PFI	\$ 43.7833

continued next page

PHARMACY BENEFACT

continued from previous page

Alberta Blue Cross® has confirmed that the shortage for Accel-Ondansetron ODT 4 mg Orally Disintegrating Tablet (DIN 02535319) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied. As a result, the LCA Price Policy will be reapplied to the following grouping effective **August 27, 2025**. The following grouping was removed from the Critical Supply Product List on **July 28, 2025**:

ONDANSETRON

4 MG ORAL DISINTEGRATING TABLET/FILM

00002535319	ACCEL-ONDANSETRON ODT	ACP	\$ 2.5450
00002511282	AURO-ONDANSETRON ODT	AUR	\$ 3.2720
00002514966	MAR-ONDANSETRON ODT	MAR	\$ 3.2720
00002487330	MINT-ONDANSETRON ODT	MPI	\$ 3.2720
00002481723	ONDANSETRON ODT	SDZ	\$ 3.2720
00002524279	ONDANSETRON ODT	SNS	\$ 3.2720
00002519232	ONDANSETRON ODT	JPC	\$ 3.2720
00002389983	ONDISSOLVE ODF	TAK	\$ 3.2720
00002519445	PMS-ONDANSETRON ODT	PMS	\$ 3.2720

Alberta Blue Cross® has confirmed that the shortage for Accel-Ondansetron ODT 8 mg Orally Disintegrating Tablet (DIN 02535327) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied. As a result, the LCA Price Policy will be reapplied to the following grouping effective **August 27, 2025**. The following grouping was removed from the Critical Supply Product List **July 28, 2025**:

ONDANSETRON

8 MG ORAL DISINTEGRATING TABLET/FILM

00002535327	ACCEL-ONDANSETRON ODT	ACP	\$ 3.8840
00002511290	AURO-ONDANSETRON ODT	AUR	\$ 4.9930
00002514974	MAR-ONDANSETRON ODT	MAR	\$ 4.9930
00002487349	MINT-ONDANSETRON ODT	MPI	\$ 4.9930
00002481731	ONDANSETRON ODT	SDZ	\$ 4.9930
00002524287	ONDANSETRON ODT	SNS	\$ 4.9930
00002519240	ONDANSETRON ODT	JPC	\$ 4.9930
00002389991	ONDISSOLVE ODF	TAK	\$ 4.9930
00002519453	PMS-ONDANSETRON ODT	PMS	\$ 4.9930

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct-bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

